What question did this study set out to answer?

The aim is to develop a novel enzyme-driven nanomachine for targeted drug delivery in cancer treatment.

May 16, 2026

Lactate-Sensitive Nanomachines for Enzyme-Controlled Drug Delivery in Cancer Therapy

MGMarta González‐JiménezUniversidad Complutense de Madrid TMTeresa MorenoUniversidad Complutense de Madrid BMBeatriz MayolUniversidad Complutense de Madrid

Key Points

The aim is to develop a novel enzyme-driven nanomachine for targeted drug delivery in cancer treatment.
Preparing mesoporous silica nanoparticles with a cyclodextrin-lactate oxidase (CD-LOx) complex for drug delivery.
Utilizing enzyme sensitivity to regulate the release of drug cargo in response to lactate levels.
Demonstrated effective control of drug release in vitro under varying lactate concentrations.
Achieved enhanced therapeutic effects in cancer cells due to targeted delivery.

Abstract

Here, we report the preparation of a novel enzyme-powered nanomachine for drug delivery system based on mesoporous silica nanoparticles capped with a cyclodextrin-lactate oxidase (CD-LOx) complex, which enables controlled cargo...

AIに質問

Bookmark

View Full Paper